Supernus Pharmaceuticals News Releases http://ir.supernus.com/ Supernus Pharmaceuticals News Releases en Supernus to Present at the Jefferies 2019 Global Healthcare Conference http://ir.supernus.com/news-releases/news-release-details/supernus-present-jefferies-2019-global-healthcare-conference ROCKVILLE, Md. , May 29, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present a Company Wed, 29 May 2019 16:15:00 -0400 Supernus Pharmaceuticals News Releases 11261 Supernus Announces First Quarter 2019 Financial Results http://ir.supernus.com/news-releases/news-release-details/supernus-announces-first-quarter-2019-financial-results Total revenue of $85.5 million and net product sales of $83.1 million . Net product sales compare to $89.1 million in 2018 and were adversely impacted by approximately $10 million in channel inventory reduction in the first quarter, coupled with seasonal insurance plan dynamics Prescription growth Tue, 07 May 2019 17:09:00 -0400 Supernus Pharmaceuticals News Releases 11236 Supernus to Host First Quarter 2019 Earnings Conference Call http://ir.supernus.com/news-releases/news-release-details/supernus-host-first-quarter-2019-earnings-conference-call ROCKVILLE, Md. , April 24, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report business Wed, 24 Apr 2019 16:15:00 -0400 Supernus Pharmaceuticals News Releases 11191 Supernus Announces Webcast of Investor Day on April 16, 2019 http://ir.supernus.com/news-releases/news-release-details/supernus-announces-webcast-investor-day-april-16-2019 ROCKVILLE, Md. , April 01, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that it will host and webcast an Investor Day on Mon, 01 Apr 2019 16:15:00 -0400 Supernus Pharmaceuticals News Releases 11146 Supernus Announces P304 Phase III Data Confirming Positive Results from Previous Three Phase III Studies on SPN-812 in ADHD http://ir.supernus.com/news-releases/news-release-details/supernus-announces-p304-phase-iii-data-confirming-positive 400 mg dose reached statistical significance compared to placebo, consistent with previous Phase III studies: •   Change versus baseline in ADHD Rating Scale 5, p-value = 0.0082 •   Effect size of 0.66 •   CGI-I secondary endpoint, p-value = 0.0051 •   Hyperactivity/Impulsivity subscale, p-value = Thu, 28 Mar 2019 08:00:00 -0400 Supernus Pharmaceuticals News Releases 11136 Supernus Hosts Conference Call to Present Topline Results of Final Phase III Study for SPN-812 in Adolescents with ADHD http://ir.supernus.com/news-releases/news-release-details/supernus-hosts-conference-call-present-topline-results-final ROCKVILLE, Md. , March 27, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that, on Thursday, March 28, 2019 , at approximately Wed, 27 Mar 2019 18:03:00 -0400 Supernus Pharmaceuticals News Releases 11121 Supernus to Present at the 2019 Cowen Health Care Conference http://ir.supernus.com/news-releases/news-release-details/supernus-present-2019-cowen-health-care-conference ROCKVILLE, Md. , March 06, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASADQ: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview Wed, 06 Mar 2019 16:10:00 -0500 Supernus Pharmaceuticals News Releases 11106 Supernus Announces Record Full Year 2018 Financial Results http://ir.supernus.com/news-releases/news-release-details/supernus-announces-record-full-year-2018-financial-results Fourth quarter 2018 total revenue of $115.9 million , a 31% increase over 2017, and fourth quarter 2018 net product sales of $113.5 million , a 32% increase over 2017. Fourth quarter 2018 operating earnings of $39.9 million , a 16% increase over 2017. Tue, 26 Feb 2019 16:56:00 -0500 Supernus Pharmaceuticals News Releases 11011 Supernus to Host Fourth Quarter and Full Year 2018 Earnings Conference Call http://ir.supernus.com/news-releases/news-release-details/supernus-host-fourth-quarter-and-full-year-2018-earnings ROCKVILLE, Md. , Feb. 12, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial Tue, 12 Feb 2019 16:15:00 -0500 Supernus Pharmaceuticals News Releases 11001 Supernus to Present at the 2019 J.P. Morgan Healthcare Conference http://ir.supernus.com/news-releases/news-release-details/supernus-present-2019-jp-morgan-healthcare-conference ROCKVILLE, Md. , Dec. 21, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview Fri, 21 Dec 2018 16:15:00 -0500 Supernus Pharmaceuticals News Releases 10961